Vivos Inc. (OTCMKTS:RDGL - Get Free Report) saw a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 2,200 shares, a decline of 99.3% from the April 30th total of 300,900 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily volume of 1,381,600 shares, the days-to-cover ratio is presently 0.0 days.
Vivos Trading Up 1.4%
Shares of OTCMKTS:RDGL traded up $0.00 during trading on Monday, reaching $0.13. The company had a trading volume of 541,709 shares, compared to its average volume of 932,640. The company has a fifty day moving average of $0.12 and a two-hundred day moving average of $0.12. Vivos has a 12 month low of $0.06 and a 12 month high of $0.26. The stock has a market capitalization of $58.96 million, a P/E ratio of -13.00 and a beta of 1.10.
About Vivos
(
Get Free Report)
Vivos Inc, a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals.
Featured Stories
Before you consider Advanced Medical Isotope, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Advanced Medical Isotope wasn't on the list.
While Advanced Medical Isotope currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.